Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

A single protein may help aggressive breast cancer spread to the brain and evade immune defenses (opens in a new tab)

medicalxpress.com · 2026-09-18

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 3 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Three of six check out. Two claims the study doesn't address.

  • 3 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedAcross several preclinical models, reducing or inhibiting SIRPα slowed tumor growth, decreased the amount of cancer found in the brain, delayed the development of brain metastases, and reversed some immune-evasion changes.View evidenceHide evidence

Why this verdict

The profile supports that SIRPα inhibition reduced TNBC brain metastatic lesions in mouse metastasis models. But the story broadens this into several unhedged preclinical effects—slowed tumor growth, delayed brain-metastasis development, and reversed immune-evasion changes—that are not established in the supplied abstract-level profile. The supported core is narrower than the claim as presented.

1

Study evidence

In mouse brain-metastasis models (intracardiac injection), inhibition of SIRPα reduced TNBC brain metastatic lesions.

“…and intracardiac-injected for brain metastasis models.”
2

Study evidence

Spatial proteomics of orthotopic and brain metastasis tissues linked SIRPα regulation to changes in the tumor immune microenvironment associated with the ECM protein fibronectin; fibronectin was reported to induce microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling immune escape.

“Digital spatial profiling was utilized to investigate the orthotopic and brain metastasis tumor immune microenvironment.”
Claim 2 of 6Not coveredBy examining human breast cancer data and tumor samples, researchers found higher SIRPα levels in TNBC cells, especially in tumors that had spread to the brain, and those higher levels were associated with poorer outcomes among patients with TNBC.View evidenceHide evidence

Why this verdict

The profile supports higher SIRPα expression in malignant TNBC epithelial cells and upregulation in patient breast-to-brain metastatic lesions. However, the supplied abstract-level profile does not report an association between higher SIRPα and poorer patient outcomes in TNBC. That outcome component cannot be verified from the provided abstract-depth evidence.

1

Study evidence

Human single-cell RNA-seq re-analysis showed increased SIRPα expression in malignant TNBC epithelial cells, and patient breast-to-brain metastatic lesions were reported to have upregulated SIRPα.

“Human breast cancer scRNAseq profiles were used to examine SIRPα expression across different cell populations and subtypes.”
Claim 3 of 6Not coveredLaboratory experiments suggested that SIRPα changes mitochondrial behavior, increasing mitochondrial fission, which made cancer cells more mobile and more likely to spread in the study models.View evidenceHide evidence

Why this verdict

The profile supports SIRPα regulation of mitochondrial dynamics/fission through SHP2/Erk/Drp1-associated signaling and links SIRPα to metastatic potential in models. However, the abstract-level profile does not detail experiments showing that mitochondrial fission specifically made cells “more mobile,” nor does it provide the full causal chain from altered mitochondrial behavior to mobility and spread. The claim may be consistent with the paper’s mechanism, but it is not fully verifiable at abstract depth.

1

Study evidence

Bulk RNA-Seq following SIRPα perturbation in TNBC cells showed changes in expression of genes involved in mitochondrial dynamics, with pathway analyses emphasizing mitochondrial fission programs as downstream of SIRPα.

“Bulk RNA sequencing was used to determine SIRPα-regulated pathway.”
2

Study evidence

Stable overexpression of SIRPα in TNBC cell lines is reported to increase mitochondrial fission and to activate signaling through SHP2, ERK, and DRP1.

“Stably SIRPα overexpressed and knockout TNBC cell lines were established to determine SIRPα intracellular regulation.”
Claim 4 of 6SupportedResearchers at Wake Forest University School of Medicine identified a protein, SIRPα, that may help aggressive breast cancer spread to the brain and escape the body's immune defenses.View evidenceHide evidence

Why this verdict

The paper profile supports the central headline claim at abstract depth: SIRPα is elevated in malignant TNBC and breast-to-brain metastatic lesions, cancer-cell SIRPα promotes metastatic behavior in preclinical models, and SIRPα/fibronectin-linked mechanisms are reported to enable immune escape. The headline is hedged with “may,” which is appropriate for preclinical/basic-research evidence.

1

Study evidence

Human single-cell RNA-seq re-analysis showed increased SIRPα expression in malignant TNBC epithelial cells, and patient breast-to-brain metastatic lesions were reported to have upregulated SIRPα.

“Human breast cancer scRNAseq profiles were used to examine SIRPα expression across different cell populations and subtypes.”
2

Study evidence

In mouse brain-metastasis models (intracardiac injection), inhibition of SIRPα reduced TNBC brain metastatic lesions.

“…and intracardiac-injected for brain metastasis models.”
Claim 5 of 6SupportedThe study found that SIRPα appears to act inside triple-negative breast cancer cells; in preclinical models, higher levels of the protein made the cancer cells more likely to spread and weakened the brain's immune response against them.View evidenceHide evidence

Why this verdict

The profile supports a cancer-cell–intrinsic role for SIRPα in TNBC cells, with overexpression increasing metastatic potential/systemic metastasis in vivo and SIRPα-associated fibronectin/microglial-tolerance mechanisms weakening antitumor immune responses in the brain-metastatic microenvironment. The claim is somewhat simplified, but its hedged, preclinical framing is consistent with the abstract-level evidence.

1

Study evidence

Stable overexpression of SIRPα in TNBC cell lines is reported to increase mitochondrial fission and to activate signaling through SHP2, ERK, and DRP1.

“Stably SIRPα overexpressed and knockout TNBC cell lines were established to determine SIRPα intracellular regulation.”
2

Study evidence

In the orthotopic mammary fat pad model using TNBC brain‑tropic cells, cancer‑cell SIRPα overexpression significantly increased systemic metastasis (abstract-reported result).

“TNBC brain-tropic cells were injected into the mouse mammary fat pad for the orthotopic tumor model…”
Claim 6 of 6SupportedThe researchers also found that SIRPα increased fibronectin production, and fibronectin appeared to weaken microglia responses so the cells became less able to trigger inflammation and attack the cancer cells.View evidenceHide evidence

Why this verdict

The profile reports SIRPα-regulated extracellular matrix/fibronectin changes and states that fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, allowing cancer cells to evade microglial immunosurveillance. The story’s hedged phrasing is aligned with the abstract-level evidence, though it omits methodological detail.

1

Study evidence

Spatial proteomics of orthotopic and brain metastasis tissues linked SIRPα regulation to changes in the tumor immune microenvironment associated with the ECM protein fibronectin; fibronectin was reported to induce microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling immune escape.

“Digital spatial profiling was utilized to investigate the orthotopic and brain metastasis tumor immune microenvironment.”
2

Study evidence

Fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling cancer to escape microglial immunosurveillance.

“Fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, allowing cancer to escape microglial immunosurveillance.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Human expression findings are observational/computational expression evidence and do not by themselves establish causality or patient prognosis.

    The story mentions preclinical status generally, but it also adds a poorer-outcomes patient association that is not present in the abstract-level profile and does not clearly distinguish expression evidence from clinical-outcome evidence.

    From in_silico scRNA-seq re-analysis and metastatic lesion expression comparison

  • Some metastasis evidence comes from specialized preclinical systems, including brain-tropic TNBC cells and intracardiac injection brain-metastasis models, which may not fully represent natural human disease progression.

    The story says “preclinical models” but does not identify that key brain-metastasis evidence used specialized mouse models and brain-tropic cells; that model context is important for interpreting translational relevance.

    From In vivo orthotopic mammary fat pad tumor implantation; in_vivo intracardiac brain metastasis model

5 things the story did carry across
  • Cancer-cell–intrinsic SIRPα is elevated in malignant TNBC epithelial cells and in patient breast-to-brain metastatic lesions.
  • SIRPα promotes mitochondrial fission through SHP2/Erk/Drp1-associated signaling in TNBC cell models.
  • In vivo mouse models show SIRPα overexpression increases metastatic potential/systemic metastasis, while SIRPα inhibition reduces brain metastatic lesion burden.
  • SIRPα-regulated fibronectin is linked to immune-microenvironment remodeling and microglial tolerance, impairing inflammatory signaling/metabolic programming and enabling immune escape.
  • The evidence is early-stage basic/preclinical research, not ready for patient testing, with safety and therapeutic translation still unresolved.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

7

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalCancer-intrinsic SIRPα drives mitochondrial fission via SHP2/Erk/Drp1-associated signaling and promotes systemic/brain metastatic potential of TNBC in vivo; SIRPα inhibition reduces brain metastatic burden in mouse models.in vivo intracardiac brain metastasis modelExpand

In plain English

In mouse metastasis models (intracardiac injection), cancer-cell–intrinsic SIRPα modulates metastatic behavior of TNBC: pharmacologic/genetic inhibition of SIRPα reduced brain metastatic lesion burden, while cancer-cell SIRPα overexpression increases metastatic potential in vivo. The study links SIRPα activity to mitochondrial fission (SHP2/Erk/Drp1) and to changes in the tumor immune microenvironment (fibronectin-associated microglial tolerance) that may facilitate brain colonization.

Key findings

  • In mouse brain-metastasis models (intracardiac injection), inhibition of SIRPα reduced TNBC brain metastatic lesions.
  • Cancer-cell SIRPα overexpression in vivo increased TNBC metastatic potential/systemic metastasis.
“…and intracardiac-injected for brain metastasis models.”
What this piece can’t prove
  • The abstract does not clearly distinguish which metastatic outcomes derive specifically from the intracardiac brain metastasis model versus other in vivo metastasis assays.

2 further details could not be confirmed from the summary.

2in silicoCancer-intrinsic SIRPα is elevated in malignant TNBC cells and in patient breast-to-brain metastatic lesions (including brain-tropic TNBC models), motivating a cancer-cell–intrinsic role in brain metastasis.in silico scRNA-seq re-analysis and metastatic lesion expression comparisonExpand

In plain English

Re-analysis of existing human breast cancer single-cell RNA-seq profiles indicated that SIRPα expression is elevated in malignant TNBC epithelial cells. Separate assessment of patient breast-to-brain metastatic lesions reported upregulation of SIRPα in those metastatic samples.

Key findings

  • Human single-cell RNA-seq re-analysis showed increased SIRPα expression in malignant TNBC epithelial cells, and patient breast-to-brain metastatic lesions were reported to have upregulated SIRPα.
“Human breast cancer scRNAseq profiles were used to examine SIRPα expression across different cell populations and subtypes.”
What this piece can’t prove
  • Unclear whether the metastatic lesion expression comparison controlled for potential confounders (e.g., tissue composition, prior treatment, patient-matching).
  • Findings are based on re-analysis/observational expression data and therefore cannot by themselves demonstrate functional or causal roles.

1 further detail could not be confirmed from the summary.

3in vitroCancer-intrinsic SIRPα drives mitochondrial fission via SHP2/Erk/Drp1-associated signaling and promotes systemic/brain metastatic potential of TNBC in vivo; SIRPα inhibition reduces brain metastatic burden in mouse models.bulk RNA-seq; differential expression; pathway enrichmentExpand

In plain English

Bulk RNA sequencing of TNBC cells with experimental perturbation of SIRPα (targeting/overexpression/knockout) identified differential expression and pathway enrichment implicating mitochondrial dynamics, with emphasis on mitochondrial fission gene programs as SIRPα-regulated.

Key findings

  • Bulk RNA-Seq following SIRPα perturbation in TNBC cells showed changes in expression of genes involved in mitochondrial dynamics, with pathway analyses emphasizing mitochondrial fission programs as downstream of SIRPα.
“Bulk RNA sequencing was used to determine SIRPα-regulated pathway.”
What this piece can’t prove
  • Pathway-level inference from bulk RNA-seq is associative; functional or mechanistic causation requires complementary experiments.
  • Findings from in vitro TNBC cell models may not fully generalize to in vivo or patient tumor contexts without supporting data.

1 further detail could not be confirmed from the summary.

4in vitroCancer-intrinsic SIRPα drives mitochondrial fission via SHP2/Erk/Drp1-associated signaling and promotes systemic/brain metastatic potential of TNBC in vivo; SIRPα inhibition reduces brain metastatic burden in mouse models.in vitro genetic perturbation and signaling/dynamics assaysExpand

In plain English

In TNBC cell lines, the authors generated stable SIRPα overexpression and knockout models and report that SIRPα modulates mitochondrial dynamics: SIRPα upregulation is associated with increased mitochondrial fission and activation of a SHP2→ERK→DRP1 signaling axis, whereas loss of SIRPα has the opposite effect. These in vitro manipulations are presented as mechanistic evidence linking cancer-intrinsic SIRPα to mitochondrial fission, which the authors state contributes to metastatic behavior.

Key findings

  • Stable overexpression of SIRPα in TNBC cell lines is reported to increase mitochondrial fission and to activate signaling through SHP2, ERK, and DRP1.
  • SIRPα knockout in TNBC cell lines is reported to reduce the mitochondrial fission phenotype and associated SHP2/ERK/DRP1 signaling relative to SIRPα-overexpressing or parental cells.
“Stably SIRPα overexpressed and knockout TNBC cell lines were established to determine SIRPα intracellular regulation.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

5in vivo animalCancer-intrinsic SIRPα drives mitochondrial fission via SHP2/Erk/Drp1-associated signaling and promotes systemic/brain metastatic potential of TNBC in vivo; SIRPα inhibition reduces brain metastatic burden in mouse models.In vivo orthotopic mammary fat pad tumor implantationExpand

In plain English

Using an orthotopic mouse mammary fat pad model with TNBC brain‑tropic cells, cancer‑cell SIRPα overexpression increased systemic metastasis in vivo. Methods reported in the abstract include orthotopic implantation of genetically modified (SIRPα-overexpressing) TNBC cells and assessment of systemic metastatic spread; numerical effect sizes, sample sizes, and statistical details are not provided in the abstract.

Key findings

  • In the orthotopic mammary fat pad model using TNBC brain‑tropic cells, cancer‑cell SIRPα overexpression significantly increased systemic metastasis (abstract-reported result).
“TNBC brain-tropic cells were injected into the mouse mammary fat pad for the orthotopic tumor model…”
What this piece can’t prove
  • Summary is based solely on abstract text; full methods, experimental details, and quantitative results are not available here.
  • Use of brain‑tropic TNBC cells in the orthotopic model may influence metastatic behavior relative to parental lines; abstract does not present comparative orthotopic data for parental vs brain‑tropic cells.

1 further detail could not be confirmed from the summary.

6ex vivo animalSIRPα-regulated extracellular matrix (notably fibronectin) reshapes the brain metastatic immune microenvironment by inducing microglial tolerance through impaired inflammatory signaling and metabolic reprogramming, enabling immune escape.Digital spatial profiling / spatial proteomics on tissue sections (orthotopic and brain metastasis)Expand

In plain English

Digital spatial proteomic profiling of orthotopic and brain metastatic tumor tissues identified SIRPα-associated changes in the tumor immune microenvironment linked to the extracellular matrix protein fibronectin; the report states fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling cancer immune escape in brain metastases.

Key findings

  • Spatial proteomics of orthotopic and brain metastasis tissues linked SIRPα regulation to changes in the tumor immune microenvironment associated with the ECM protein fibronectin; fibronectin was reported to induce microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling immune escape.
“Digital spatial profiling was utilized to investigate the orthotopic and brain metastasis tumor immune microenvironment.”
What this piece can’t prove
  • It is not specified whether the spatial proteomic observations represent causal mechanisms versus correlative associations in the tumor microenvironment.

2 further details could not be confirmed from the summary.

7otherSIRPα-regulated extracellular matrix (notably fibronectin) reshapes the brain metastatic immune microenvironment by inducing microglial tolerance through impaired inflammatory signaling and metabolic reprogramming, enabling immune escape.Expand

In plain English

The paper reports that SIRPα-regulated extracellular matrix protein fibronectin is associated with reshaping the brain-metastatic tumor immune microenvironment and functionally induces microglial tolerance by impairing inflammatory signaling and altering microglial metabolic programming, enabling cancer immune escape.

Key findings

  • Fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling cancer to escape microglial immunosurveillance.
“Fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, allowing cancer to escape microglial immunosurveillance.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

And 9 more candidates considered.